Roche (company)
Roche looks to expand and upgrade US research centers as part of $50B investment strategy in the country
Roche (company), Indiana, United States, Investments, expansion, Pennsylvania, Expanding, upgrade, Research Organization
Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
OBT, therapeutic autologous dendritic cells, Roche (company), Partnership, Oxford BioTherapeutics, Antibody-Drug Conjugates, biobucks, New
Ascletis’ Oral GLP-1 Drug Shows Promising Early Results in Obesity Treatment, Rivaling Roche’s Candidate
Ascletis Pharma, obesity treatment, oral GLP-1 receptor agonist, ASC30, weight loss, clinical trials, Roche, CT-996, pharmaceutical competition
Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments
Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators
Newleos Therapeutics Launches with $93.5M to Develop Novel Neuropsychiatric Treatments
Newleos Therapeutics, Longwood Fund, neuropsychiatry, anxiety disorders, substance use disorders, Roche, GABA A -γ1, clinical trials
FDA Approves Evrysdi Tablets: A Breakthrough in Convenient SMA Treatment
Evrysdi, risdiplam, spinal muscular atrophy (SMA), FDA approval, tablet formulation, oral treatment, Genentech, Roche
Roche’s Gazyva Shows Promising Results in Phase III Lupus Nephritis Trial
Gazyva, obinutuzumab, lupus nephritis, Phase III REGENCY trial, complete renal response, Roche, autoimmune disease, kidney function
FDA Approves Roche’s Susvimo for Diabetic Macular Edema: A Breakthrough in Continuous Delivery Eye Treatment
Susvimo, ranibizumab, diabetic macular edema, DME, Roche, FDA approval, continuous delivery, eye implant, vision improvement
FDA Approves Roche’s PATHWAY HER2 Test for HER2-Ultralow Metastatic Breast Cancer
Roche, PATHWAY HER2 (4B5) test, FDA approval, HER2-ultralow, metastatic breast cancer, companion diagnostic, Enhertu, personalized medicine